Ondansetron Stada (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetron Stada, is a 5-HT3 receptor antagonist presented as a tablet for oral use. It treats nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult and pediatric patients. GNH USA supplies Ondansetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondansetron Stada is a selective 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting in several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: helps reduce the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: provides prophylactic control of nausea during and after radiation treatment. - Post‑operative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑related hyperemesis gravidarum (off‑label in some regions): may be used when conventional therapies are ineffective.

Side effects reported with ondansetron are generally mild to moderate and vary with the route of administration and patient population.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel motility changes. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: mild vertigo or light‑headedness.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with intravenous use. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Vision changes: blurred vision or visual disturbances.

When prescribing ondansetron, clinicians should consider patient‑specific factors and monitor for potential adverse events.

- Cardiac risk assessment: evaluate baseline ECG in patients with known cardiac disease or electrolyte abnormalities. - Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome when used with other serotonergic agents. - Electrolyte balance: correct hypokalaemia or hypomagnesemia before initiating therapy. - Pregnancy and lactation: use only if the potential benefit outweighs the risk; discuss with the patient. - Renal or hepatic impairment: dose adjustment may be required; monitor organ function. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Certain C‑ C       ---

Moderate  ---  --- --- ---

-